Invasive, deadly fungus affecting bats found in Rocky Mountain National Park
DENVER (KDVR) — An invasive fungus has been detected in bats at Rocky Mountain National Park.
In a Thursday press release from the national park, tests done by the U.S. Geological Survey confirmed the fungus known as Pseudogymnoascus destructans, or Pd, has been detected in bats in the Holzwarth Historic Site on the west side of Rocky Mountain National Park.
According to the park, this is the first confirmed detection of the fungus in Grand County.
Pd is described as an invasive fungus that causes white-nose syndrome — a deadly and infectious disease that impacts bats.
'Any new detection of Pd is worrisome because bats are vital for healthy ecosystems. Rocky Mountain National Park is home to nine known species of bats, five of which have been found living in areas above 11,000 feet,' said Rocky Mountain National Park in a press release.
How much snow will fall in the high country this weekend?
While white-nose syndrome does not pose a risk to humans, people can spread the disease.
Following the detection, Rocky Mountain National Park has provided protection tips to visitors. The park asks people to report dead or injured bats to park personnel. The park also said people should never touch a bat, because they could carry other dangerous diseases aside from white-nose syndrome.
If you do visit a cave or bat habitat, Rocky Mountain National Park recommends you properly decontaminate gear and outerwear.
The national park said white-nose syndrome was first confirmed in 2022 in southeastern Colorado, it has also been confirmed in Larimer County.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Alabama Dept. of Public Health reports no measles detected after investigation
COLUMBUS, Ga. () — The Alabama Department of Public Health (ADPH) has determined that the unvaccinated person being investigated in Lee County, Alabama, does not have measles. The ADPH says that due to the extremely contagious risk of measles in unvaccinated people, they regularly launch investigations on suspected cases to ensure that vulnerable and potentially exposed people are informed and protected. 'This investigation began on Saturday afternoon. I appreciate the quick response of the ADPH on call team to ensure that all the response elements were in place, in order to protect Alabama.' ADPH Chief Medical Officer, Dr. Karen Landers said. 'While ADPH has determined that this is not a case of measles, I urge all Alabamians to be vigilant in ensuring that eligible persons are up to date on the MMR vaccine. The MMR vaccine is safe and effective. High rates of MMR vaccine in our state will protect our children, our families, and our citizens from this severe and deadly disease.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Jim Cramer on Cardinal Health: 'I am a Believer'
Cardinal Health, Inc. (NYSE:CAH) is one of the 11 stocks on Jim Cramer's radar. Calling Cardinal Health, Inc.'s (NYSE:CAH) upcoming Investor Day a possible needle mover, Cramer said: 'Now, Thursday brings some analyst meetings that could move the needle. Cardinal Health, we've had them on a couple of times, tells a terrific story about how it's much more than a drug middleman. And I believe, I am a believer.' A senior physician in a modern healthcare institution administering medication to a patient. Cardinal Health (NYSE:CAH) provides medical products and services used in various care settings. The company delivers pharmaceuticals, equipment, and support tools while managing distribution, logistics, and pharmacy operations through healthcare-focused technology. On May 14, Cramer extensively commented on the company as he said: 'These stocks, namely Cardinal Health, Cencora, and McKesson, are seemingly perpetual residents on the new high list. Over the long haul, they're some of the best performers out there, and they've done great this year, as is pretty much always the case. And yet, doesn't it always feel like the drug distributors are just one bad day away from falling apart… Let's not forget that the drug distributors are making fortunes right now. Cardinal Health turned in an excellent set of numbers two weeks ago with double-digit earnings growth. Management put through a big boost in their full-year earnings forecast. Cardinal stock jumped 3% in response, climbing from $141 to $145, and it kept running for really a week after that, eventually setting at an all-time high of $154 just last Thursday. What a fabulous move… While we acknowledge the potential of CAH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
an hour ago
- Yahoo
Merck's Cholesterol Medication Achieves Primary Endpoint in Two Trials
Merck & Co., Inc. (NYSE:MRK) is one of the best Dow stocks to invest in. On June 9, the company announced that its drug, enlicitide decanoate, achieved its primary goal of lowering a specific type of cholesterol in two late-stage clinical trials. A close-up of a person's hand holding a bottle of pharmaceuticals. The medication is being studied as a potential treatment for hyperlipidemia, a condition marked by high levels of fat in the bloodstream. According to the company, enlicitide led to significant reductions in LDL-C, or "bad" cholesterol, in patients with existing heart disease or those at risk of developing it. Merck & Co., Inc. (NYSE:MRK) is a global healthcare organization focused on providing innovative health solutions through its medicines, vaccines, biologic therapies, and animal health products. The stock has surged by over 1% in the past month. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Sign in to access your portfolio